OMEROS CORP Grants Receivable, Current
OMEROS CORP (OMER) had Grants Receivable, Current of $0 as of 2016-12-31, per its 10-K filed 2017-03-16.
Discontinued › Notes › and Others › Nontrade Receivables, Current
us-gaap:GrantsReceivableCurrent · last filed 2017-03-16
- 2016-12-31: Grants Receivable, Current $0.00.
- 2015-12-31: Grants Receivable, Current $136.00K.
- 2014-12-31: Grants Receivable, Current $324.00K.
- 2013-12-31: Grants Receivable, Current $308.00K.
| Period end | Grants Receivable, Current |
|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-03-16 |
| 2015-12-31 | $136.00K 10-K · filed 2017-03-16 |
| 2014-12-31 | $324.00K 10-K · filed 2016-03-15 |
| 2013-12-31 | $308.00K 10-K · filed 2015-03-16 |
| 2012-12-31 | $402.00K 10-K · filed 2014-03-13 |
| 2011-12-31 | $862.00K 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |